With that in mind, let's delve into the average projections of some Haemonetics metrics that are commonly tracked and projected by analysts on Wall Street. Wall Street analysts expect Haemonetics (HAE) to post quarterly earnings of $1.22 per share in its upcoming report, which indicates a year-over-year increase of 35.6%. Revenues are expected to be $327.34 million, down 4.7% from the year-ago quarter. The consensus EPS estimate for the quarter has undergone a downward revision of 3.3% in the past 30 days, ...

Wall Street analysts forecast that Epam (EPAM) will report quarterly earnings of $2.27 per share in its upcoming release, pointing to a year-over-year decline of 7.7%. It is anticipated that revenues will amount to $1.28 billion, exhibiting an increase of 10.1% compared to the year-ago quarter.The consensus EPS estimate for the quarter has undergone a downward revision of 5.6% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassessed their ...

Group 1 - The AZEK Company is expected to report quarterly earnings of $0.44 per share, reflecting a 12.8% increase year over year [1] - Analysts forecast revenues of $443.6 million, indicating a 6% year-over-year growth [1] - There has been no revision in the consensus EPS estimate for the quarter over the past 30 days, suggesting stability in analysts' projections [1] Group 2 - Analysts project 'Net Sales- Commercial' to reach $15.07 million, a decrease of 5% from the prior-year quarter [4] - The estimated 'Net Sales- Residential' is $431.37 million, representing a 7.2% increase year over year [4] - The average prediction for 'Adjusted EBITDA- Residential' is $119.21 million, up from $110.39 million in the previous year [4] Group 3 - Shares of The AZEK Company have increased by 8.1% in the past month, outperforming the Zacks S&P 500 composite, which moved up by 0.4% [5] - The company holds a Zacks Rank 3 (Hold), indicating it is expected to perform in line with the overall market in the near future [5]

Core Viewpoint - Nutrien (NTR) is expected to report a quarterly earnings per share (EPS) of $0.33, reflecting a 28.3% decline year-over-year, with revenues forecasted at $5.32 billion, a decrease of 1.2% from the previous year [1]. Earnings Estimates - The consensus EPS estimate has been revised 0.5% higher in the last 30 days, indicating a collective reevaluation by analysts [2]. - Revisions to earnings projections are crucial for predicting investor behavior and stock performance [3]. Sales and Revenue Projections - Analysts predict 'Sales- Retail Total' to reach $3.49 billion, marking a 5.6% increase from the year-ago quarter [4]. - 'Sales- Nitrogen' is expected to be $972.08 million, down 5.4% year-over-year [5]. - 'Sales- Potash' is forecasted at $783.90 million, indicating a 15.4% decline from the prior year [5]. - 'Sales- Phosphate' is estimated at $435.19 million, reflecting a 12.8% decrease from the previous year [5]. Volume and Pricing Estimates - 'Tonnes Sold - Potash - Total' is projected at 3,255.30 KTon, down from 3,413 KTon year-over-year [6]. - 'Tonnes Sold - Nitrogen' is expected to be 2,473.23 KTon, slightly down from 2,507 KTon [6]. - The average selling price for 'Phosphate - Industrial and feed' is estimated at $777.80 per tonne, down from $848 per tonne in the same quarter last year [7]. - The average selling price for 'Phosphate - Total' is projected at $614.19 per tonne, compared to $689 per tonne a year ago [7]. - 'Average Selling Price per Tonne - Nitrogen - Solutions, nitrates and sulphates' is expected to be $220.56 per tonne, down from $226 per tonne [8]. - 'Average Selling Price per Tonne - Nitrogen - Urea and ESN' is estimated at $410.89 per tonne, compared to $432 per tonne last year [8]. - 'Average Selling Price per Tonne - Nitrogen - Ammonia' is forecasted at $417.19 per tonne, slightly up from $403 per tonne [9]. - 'Tonnes Sold - Phosphate' is expected to be 569.00 KTon, down from 620 KTon in the same quarter last year [9]. Stock Performance - Over the past month, Nutrien shares have returned +11.9%, while the Zacks S&P 500 composite has seen a -0.5% change [9]. - Nutrien currently holds a Zacks Rank 3 (Hold), suggesting its performance may align with the overall market in the near future [10].

Core Viewpoint - Cencora (COR) is expected to report quarterly earnings of $4.08 per share, reflecting a 7.4% increase year-over-year, with revenues projected at $74.82 billion, indicating a 9.4% growth compared to the previous year [1]. Earnings Projections - The consensus EPS estimate has been revised upward by 0.2% in the last 30 days, showcasing analysts' reassessment of their initial projections [2]. - Changes in earnings projections are crucial for predicting investor reactions, as empirical studies show a strong correlation between earnings estimate trends and short-term stock price movements [3]. Revenue Estimates - Analysts estimate 'Revenue- Total International Healthcare Solutions' at $7.36 billion, a year-over-year increase of 3.3% [5]. - The consensus for 'Revenue- Total U.S. Healthcare Solutions' is $67.56 billion, reflecting a 10.2% increase from the same quarter last year [5]. - 'Revenue- International Healthcare Solutions- Alliance Healthcare' is projected to reach $5.98 billion, indicating a 3.9% year-over-year change [6]. - 'Revenue- U.S. Healthcare Solutions- Animal Health' is expected to be $1.49 billion, suggesting a 14.1% increase year-over-year [6]. - 'Revenue- U.S. Healthcare Solutions- Human Health' is forecasted at $65.56 billion, reflecting a 9.3% year-over-year growth [6]. - 'Revenue- International Healthcare Solutions- Other Healthcare Solutions' is estimated at $1.42 billion, indicating a 3.8% increase from the previous year [7]. Operating Income Estimates - Analysts project 'Operating income- Non-GAAP- International Healthcare Solutions' to be $182.43 million, down from $192.72 million reported in the same quarter last year [7]. - 'Operating income- Non-GAAP- U.S. Healthcare Solutions' is expected to reach $926.36 million, compared to $841.06 million from the previous year [8]. Stock Performance - Over the past month, Cencora shares have returned +0.4%, outperforming the Zacks S&P 500 composite, which recorded a -0.5% change [8].

Core Viewpoint - Mettler-Toledo (MTD) is expected to report a quarterly earnings per share (EPS) of $7.90, reflecting an 11.1% year-over-year decline, with revenues projected at $875.01 million, down 5.5% from the previous year [1]. Earnings Estimates - The consensus EPS estimate has remained unchanged over the past 30 days, indicating that analysts have not revised their projections during this period [2]. - Revisions to earnings projections are crucial for predicting investor behavior and are linked to short-term stock price performance [3]. Revenue and Sales Projections - Analysts estimate 'Net sales- Products' at $670.72 million, representing a 4.3% decline year-over-year [5]. - 'Net sales- Service (Point in Time+Over Time)' is projected to be $208.59 million, indicating a 7.3% decrease from the year-ago quarter [5]. - 'Net sales- Retail' is expected to reach $42.69 million, reflecting a 13% year-over-year decline [5]. - 'Net sales- Industrial' is forecasted at $332.70 million, showing a 5.4% decrease from the prior-year quarter [6]. - 'Net sales- Laboratory' is anticipated to be $495.28 million, indicating a 5.7% decline from the previous year [6]. Stock Performance - Mettler-Toledo shares have experienced a return of -7.9% over the past month, compared to a -0.2% change in the Zacks S&P 500 composite [6]. - The company holds a Zacks Rank of 3 (Hold), suggesting it is expected to perform in line with the overall market in the near future [6].

The upcoming report from Monolithic Power (MPWR) is expected to reveal quarterly earnings of $4 per share, indicating an increase of 42.4% compared to the year-ago period. Analysts forecast revenues of $632.18 million, representing an increase of 38.1% year over year.Over the last 30 days, there has been no revision in the consensus EPS estimate for the quarter. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe.Before a company reve ...

Core Insights - Analysts forecast Eaton (ETN) to report quarterly earnings of $2.70 per share, reflecting a year-over-year increase of 12.5% [1] - Expected revenues are projected to be $6.27 billion, indicating a 5.4% increase compared to the same quarter last year [1] Earnings Estimates - The consensus EPS estimate has been revised down by 0.7% in the past 30 days [2] - Revisions to earnings projections are critical for predicting investor behavior and stock price performance [3] Key Metrics Projections - Analysts estimate 'Net Sales- eMobility' to reach $166.27 million, a year-over-year increase of 5.2% [4] - 'Net Sales- Aerospace' is expected to be $943.53 million, reflecting an 8.3% year-over-year increase [5] - 'Net Sales- Vehicle' is projected at $665.06 million, indicating a decline of 8.1% year-over-year [5] - 'Net Sales- Electrical Global' is anticipated to be $1.55 billion, showing a 3.6% increase from the prior year [5] - 'Net Sales- Electrical Americas' is expected to reach $2.95 billion, a 9.6% increase from the previous year [6] Segment Operating Profit Estimates - 'Segment operating profit (loss)- Aerospace' is projected at $215.76 million, up from $201 million year-over-year [6] - 'Segment operating profit (loss)- Vehicle' is estimated at $109.81 million, down from $116 million year-over-year [7] - 'Segment operating profit (loss)- Electrical Global' is expected to be $287.33 million, an increase from $274 million year-over-year [7] - 'Segment operating profit (loss)- Electrical Americas' is projected at $887.36 million, compared to $785 million from the previous year [8] Stock Performance - Eaton shares have increased by 5.9% over the past month, contrasting with a -0.8% change in the Zacks S&P 500 composite [9] - Eaton holds a Zacks Rank 3 (Hold), indicating expected performance in line with the overall market [9]

In its upcoming report, Exelon (EXC) is predicted by Wall Street analysts to post quarterly earnings of $0.78 per share, reflecting an increase of 13% compared to the same period last year. Revenues are forecasted to be $6.36 billion, representing a year-over-year increase of 5.3%. Over the past 30 days, the consensus EPS estimate for the quarter has been adjusted downward by 6% to its current level. This demonstrates the covering analysts' collective reassessment of their initial projections during this pe ...

Core Viewpoint - Analysts expect Sirius XM to report quarterly earnings of $0.70 per share, indicating no change from the previous year, with revenues projected at $2.08 billion, down 3.7% year-over-year [1]. Revenue Estimates - Total revenue for Sirius XM is estimated at $1.59 billion, reflecting a year-over-year decline of 4.3% [4]. - Revenue from Pandora and Off-platform is projected to be $482.97 million, down 2.4% from the prior year [4]. - Subscriber revenue for Sirius XM is expected to reach $1.48 billion, indicating a decrease of 4.2% year-over-year [5]. - Advertising revenue for Sirius XM is estimated at $38.36 million, down 4.1% from the previous year [5]. - Equipment revenue is projected to be $44.79 million, reflecting a significant decline of 10.4% year-over-year [6]. Subscriber Metrics - Ending subscribers for Sirius XM are expected to total 32,862, down from 33,430 in the same quarter last year [7]. - Ending subscribers for Pandora and Off-platform are projected at 5,687, compared to 5,944 in the same quarter last year [8]. - Self-pay subscribers for Sirius XM are forecasted to be 31,223, down from 31,583 year-over-year [8]. - Paid promotional subscribers are expected to be 1,693, compared to 1,847 in the previous year [9]. Average Revenue Per User (ARPU) - Analysts predict that the ARPU for Sirius XM will reach $15.06, down from $15.36 in the same quarter last year [9]. Stock Performance - Sirius XM shares have shown a return of -4.8% over the past month, compared to the Zacks S&P 500 composite's -4.3% change [10].